Literature DB >> 3539713

Protein metabolism in inflammatory bowel disease.

J Powell-Tuck.   

Abstract

Major loss of body protein mass in inflammatory bowel disease is much less common than weight loss, which is often attributable to losses of other body, particularly water and fat. It does occur, however, in a few patients, especially in those with compromised food intake. It is due principally to the combined effects of diminished intake and excessive intestinal losses of amino nitrogen. Nitrogen metabolism is influenced not only by protein nutritional state and net nitrogen intake but also by disease activity. There is some evidence for abnormally low secretion of growth hormone in adolescents with inflammatory bowel disease and growth failure. Low serum albumin concentrations are not necessarily related to protein undernutrition and are the combined result of relatively reduced albumin synthesis, increased intestinal losses, and maldistribution between intravascular and extravascular spaces. Concentrations in the plasma of IgG and acute phase reactants may be raised despite increased losses into the bowel lumen. The prevention of total body protein depletion is achieved principally by maintaining adequate and often not supranormal intakes of a balanced source of amino nitrogen in a balanced diet given orally, enterally, or parenterally, combined with a medical or surgical approach to reduce disease activity: supranormal energy intakes are not beneficial.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539713      PMCID: PMC1434623          DOI: 10.1136/gut.27.suppl_1.67

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  The digestion and absorption of protein by normal man.

Authors:  C W CRANE; A NEUBERGER
Journal:  Biochem J       Date:  1960-02       Impact factor: 3.857

2.  METABOLIC STUDIES ON CHRONIC ULCERATIVE COLITIS.

Authors:  C S Welch; M Adams; E G Wakefield
Journal:  J Clin Invest       Date:  1937-01       Impact factor: 14.808

3.  Fecal radioiodide excretion following intravenous injection of 131-I-albumin and 125-I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis.

Authors:  S Jarnum; K B Jensen
Journal:  Gastroenterology       Date:  1975-06       Impact factor: 22.682

4.  Undernutrition and surgery in regional ileitis.

Authors:  R G Clark; N M Lauder
Journal:  Br J Surg       Date:  1969-10       Impact factor: 6.939

5.  The endocrinology of anorexia nervosa.

Authors:  P J Beumont
Journal:  Med J Aust       Date:  1979-06-30       Impact factor: 7.738

6.  Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease.

Authors:  A Tenore; W F Berman; J S Parks; A M Bongiovanni
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

7.  Nyctohemeral growth hormone levels in children with growth retardation and inflammatory bowel disease.

Authors:  R W Gotlin; R S Dubois
Journal:  Gut       Date:  1973-03       Impact factor: 23.059

8.  Rate and pattern of epithelial cell proliferation in ulcerative colitis.

Authors:  E P Serafini; A P Kirk; T J Chambers
Journal:  Gut       Date:  1981-08       Impact factor: 23.059

9.  The effect of insulin infusion on whole-body protein metabolism in patients with gastrointestinal disease fed parenterally.

Authors:  J Powell-Tuck; M J Glynn
Journal:  Hum Nutr Clin Nutr       Date:  1985-05

Review 10.  Anorexia nervosa.

Authors:  A D Schwabe; B M Lippe; R J Chang; M A Pops; J Yager
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  5 in total

1.  Protein synthesis rates in colon and liver: stimulation by gastrointestinal pathologies.

Authors:  S D Heys; K G Park; M A McNurlan; R A Keenan; J D Miller; O Eremin; P J Garlick
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.

Authors:  María José García; Juan Carlos Rodríguez-Duque; Marta Pascual; Coral Rivas; Beatriz Castro; Sandra Raso; Marcos López-Hoyos; María Teresa Arias-Loste; Montserrat Rivero
Journal:  Therap Adv Gastroenterol       Date:  2022-03-02       Impact factor: 4.409

3.  Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.

Authors:  Sarah Alrubia; Jialin Mao; Yuan Chen; Jill Barber; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2022-09-03       Impact factor: 5.577

4.  Anti-inflammatory Streptococcus thermophilus CNRZ160 limits sarcopenia induced by low-grade inflammation in older adult rats.

Authors:  Isabelle Savary-Auzeloux; Marianne Jarzaguet; Carole Migné; Jean-Louis Kemeny; Lorraine Novais-Gameiro; Marcela de Azevedo; Véronique Mathé; François Mariotti; Philippe Langella; Jean-Marc Chatel; Dominique Dardevet
Journal:  Front Nutr       Date:  2022-09-29

5.  Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease.

Authors:  Seung Hyuk Kim; You Sun Kim; Si Hyeong Lee; Hyun Mi Lee; Won Eui Yoon; Seo Hyun Kim; Hee Jun Myung; Jeong Seop Moon
Journal:  Intest Res       Date:  2021-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.